Revolade

Active Substance: eltrombopag olamine
Common Name: eltrombopag
ATC Code: B02BX05
Marketing Authorisation Holder: GlaxoSmithKline Trading Services Ltd.
Active Substance: eltrombopag olamine
Status: Authorised
Authorisation Date: 2010-03-11
Therapeutic Area: Purpura, Thrombocytopenic, Idiopathic
Pharmacotherapeutic Group: Antihaemorrhagics, other systemic hemostatics

Therapeutic Indication

Revolade is indicated for adult chronic-immune (idiopathic)-thrombocytopenic-purpura (ITP) splenectomised patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

Revolade may be considered as second-line treatment for adult non-splenectomised patients where surgery is contraindicated.

Revolade is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.

What is Revolade?

Revolade is medicine that contains the active substance eltrombopag. It is available as tablets (25, 50 and 75 mg).

What is Revolade used for?

Revolade is used in adults with long-term immune thrombocytopenic purpura (ITP), a disease in which the patient’s immune system destroys the platelets (components in the blood that help it to clot). Patients with ITP have low platelet counts in the blood (thrombocytopenia) and are at risk of bleeding. Revolade is used in patients who have had their spleen removed and who do not respond to treatment with medicines such as corticosteroids or immunoglobulins. It can also be considered for use in patients who have previously been treated for ITP who cannot have surgery to remove their spleen. The spleen is an organ that is involved in the destruction of platelets.

Revolade is also used to treat thrombocytopenia in adults with chronic (long-term) hepatitis C, a disease of the liver caused by infection with the hepatitis C virus, when the severity of thrombocytopenia is preventing antiviral therapy.

The medicine can only be obtained with a prescription.

How is Revolade used?

Treatment with Revolade should be started and supervised by a doctor who has experience in treating blood diseases or hepatitis C.

In adults with ITP, the recommended starting dose is 50 mg once a day, except in patients of East Asian descent (such as Japanese, Chinese, Taiwanese or Korean) where it should be 25 mg once a day. After treatment has started, the dose should be adjusted for each patient with the aim of keeping the level of platelets high enough to prevent bleeding (above 50,000 platelets per microlitre). The daily dose should not exceed 75 mg.

In adults with thrombocytopenia associated with hepatitis C, the recommended starting dose is 25 mg once a day in patients of all ethnicities. After treatment with Revolade has started, the level of platelets should be monitored and the dose of Revolade adjusted as necessary every 2 weeks in order to achieve levels of platelets that allow antiviral therapy for hepatitis C to be started. Monitoring should continue during hepatitis C therapy and the dose of Revolade should be adjusted to keep the level of platelets high enough (around 50,000 to 75,000 per microlitre) to prevent bleeding or the need to reduce the antiviral dose. The daily dose of Revolade should not exceed 100 mg.

Patients should not take any antacids, dairy products or mineral supplements for four hours before or four hours after taking Revolade. For more information, see the summary of product characteristics (also part of the EPAR).

How does Revolade work?

In the body, a hormone called ‘thrombopoietin’ stimulates the production of platelets by attaching to certain receptors in the bone marrow. The active substance in Revolade, eltrombopag, attaches to and stimulates the same receptors as thrombopoietin. This leads to an increased production of platelets.

How has Revolade been studied?

For the treatment of ITP, Revolade was compared with placebo (a dummy treatment) in two main studies involving a total of 311 adults with chronic ITP. The patients had previously been treated but the treatments had not worked or the disease had come back. All of the patients had a platelet count of less than 30,000 per microlitre at the start of the studies. In the first study, the main measure of effectiveness was the number of patients whose platelet count had increased to at least 50,000 cells per microlitre after six weeks. In the second study, it was the number of patients who had a platelet count between 50,000 and 400,000 per microlitre during six months of treatment.

For the treatment of thrombocytopenia associated with hepatitis C, two main studies involving a total of 1,441 adults were carried out. These compared Revolade with placebo for allowing the starting and maintenance of antiviral treatment in patients with hepatitis C whose platelet count was initially too low to allow starting such treatment (less than 75,000 per microlitre). In both studies, the main measure of effectiveness was the number of patients whose blood tests did not show any sign of hepatitis C virus 6 months after the end of treatment.

What benefit has Revolade shown during the studies?

In the treatment of chronic ITP, Revolade was more effective than placebo. In the first ITP study, 59% of the patients who took Revolade (43 out of 73) had a platelet count of at least 50,000 per microlitre after six weeks, compared with 16% of those who took placebo (6 out of 37). In the second ITP study, patients taking Revolade were around eight times more likely than those taking placebo to reach a platelet count of between 50,000 and 400,000 per microlitre during the six months of treatment.

In the treatment of thrombocytopenia associated with hepatitis C, a higher proportion of patients who took Revolade tested negative for hepatitis C, compared with those who took placebo (23% versus 14% in the first study, and 19% versus 13% in the second study).

What is the risk associated with Revolade?

The most common side effects with Revolade (seen in more than 1 patient in 10) are headache, anaemia (low red blood cell counts), decreased appetite, insomnia (difficulty sleeping), cough, nausea (feeling sick), diarrhoea, pruritus (itching), alopecia (hair loss), myalgia (muscle pain), pyrexia (fever), fatigue (tiredness), influenza (flu)-like illness, asthenia (weakness), chills and peripheral oedema (swelling, especially of the ankles and feet). There is also a risk of liver problems and thromboembolic complications (problems with clots in blood vessels). Bleeding can also come back after the medicine is stopped. For the full list of all side effects reported with Revolade, see the package leaflet.

Revolade must not be used in people who are hypersensitive (allergic) to active substance or any of the other ingredients. The medicine should be used with caution in patients who have liver problems. For more information, see the summary of product characteristics.

Why has Revolade been approved?

The CHMP decided that Revolade’s benefits are greater than its risks and recommended that it be given marketing authorisation.

What measures are being taken to ensure the safe use of Revolade?

A risk management plan has been developed to ensure that Revolade is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Revolade, including the appropriate precautions to be followed by healthcare professionals and patients.

In addition, the company that makes Revolade will ensure that doctors in all Member States who will prescribe the medicine are provided with educational materials reminding them how the medicine should be used and of the medicine’s possible side effects such as liver problems, thromboembolic complications and the recurrence of bleeding.

Other information about Revolade

The European Commission granted a marketing authorisation valid throughout the European Union for Revolade on 11 March 2010.

For more information about treatment with Revolade, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web1)